Paul is a specialist in cancer drug discovery, with 27 years’ experience at AstraZeneca, where he provided project and scientific leadership for collaborative cross-functional delivery of small molecule and therapeutic antibody projects across all stages of drug discovery. Paul specifically developed translational science and delivery plans for biomarker strategies for proof of mechanism studies and patient selection.
Ask me about: the Foundation's translational medicine and research.